KOSPIBiotech & Pharma0120G0

Samyang Biopharm

₩39,400▼ 0.25%2026-11-18 close
Market Cap
₩293B
Turnover
₩600M
Volume
10K
Shares out.
7.4M
PER
—
PBR
1.3×
EPS
—
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Suture leadership anchors a push into oncology and platforms

Samyang Biopharm rests on global suture leadership and an oncology injectable plant, but a third-quarter 2026 attributable net loss has put earnings stability in focus.

  1. 1

    Became an independent company through a spin-off in November 2025; the disclosed 2025 figures cover only the two months from November to December, with revenue of KRW 28.6 billion and an operating margin of 9.4%.

  2. 2

    Second-quarter 2026 revenue rose to KRW 35.9 billion, yet operating profit and attributable net income fell; the third quarter swung to an attributable net loss of KRW 174 million.

  3. 3

    Sutures hold the global number one position by thread supply volume and, per company statements, account for 45% of revenue, which points to concentration.

  4. 4

    A dedicated cytotoxic injectable plant with annual capacity of 5 million vials, certified under Japanese and European GMP, is presented as the oncology differentiator.

  5. 5

    The SENS delivery platform and a generic of Jakavi are the medium-term variables; industry expectations point to a possible launch after June 2028.

02

Business structure

Samyang Biopharm was spun off from Samyang Holdings on November 1, 2025 and relisted on the KOSPI on November 24, 2025. Its business spans biodegradable sutures, aesthetic medical devices, oncology drugs and drug delivery technology.

In the two months from November 1 to December 31, 2025, the medical device segment generated revenue of KRW 17.9 billion and operating profit of KRW 6.1 billion, making it the largest profit contributor.

The pharmaceutical segment posted revenue of KRW 10.6 billion and operating profit of KRW 1.0 billion, while the other segment recorded a loss. Per company statements cited in the press, sutures account for 45% of revenue and the company holds the global number one share by thread supply volume.

Over the same two months, exports were KRW 16.8 billion and domestic sales were KRW 11.8 billion, an export share of about 59%. Another press report said more than 80% of revenue comes from overseas, so the basis of the figures differs.

The oncology portfolio covers seven solid tumor types and five blood cancers, and a dedicated cytotoxic injectable plant with annual capacity of 5 million vials holds both Japanese and European GMP certifications.

The aesthetic lineup includes the Croquie thread lift and the Lapulen filler, which launched in Indonesia in 2023 and was supported by a China partnership signed the same year.

In anticancer contract manufacturing it competes with large CDMO players such as Samsung Biologics, and it positions its dedicated facility and dual GMP certification as differentiators.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3———
2025Q4———
2026Q1₩31.2B₩1.4B4.4%
2026Q2₩35.9B₩700M2.1%
2026Q3₩33B₩900M2.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2025₩28.6B₩2.7B₩2.2B9.4%1.0%44.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

The disclosed annual figures are labeled as 2025, but they actually cover only the two months from the November 1, 2025 spin-off date to December 31. Revenue was KRW 28.6 billion and operating profit was KRW 2.69 billion, an operating margin of 9.4%.

Attributable net income was KRW 2.24 billion, and net income including non-controlling interests was also KRW 2.24 billion. Operating cash flow was KRW 9.77 billion.

Total equity at the end of 2025 was KRW 234.7 billion, all of it attributable to shareholders of the parent, with total liabilities of KRW 104.5 billion and a debt-to-equity ratio of 44.5%. No quarterly disclosures exist for the third and fourth quarters of 2025, so year-on-year quarterly comparisons are not possible.

First-quarter 2026 revenue was KRW 31.2 billion, operating profit KRW 1.39 billion and attributable net income KRW 2.57 billion. Second-quarter revenue rose 15.0% quarter on quarter to KRW 35.9 billion, but operating profit fell 46.2% to KRW 746 million and attributable net income fell 48.2% to KRW 1.33 billion.

Revenue growth did not carry through to profit in that quarter, and the cause should be checked in the quarterly report body. Third-quarter revenue was KRW 33 billion, down 7.9%, while operating profit rose 17.8% to KRW 879 million.

However, the company posted an attributable net loss of KRW 174 million, a swing into loss from the prior quarter. The gap between operating profit and net income, including non-operating items and taxes, is the key point to check. Research and development spending over the two months from November to December 2025 reached KRW 4.99 billion.

05

Industry analysis

In sutures, Samyang Biopharm holds the global number one share by thread supply volume and, according to press reports, supplies roughly 200 companies in about 50 countries. Sutures account for 45% of revenue per company statements, so a single product group carries much of the earnings.

Demand for aesthetic procedures is rising globally, and the company is accelerating entry with fillers and thread lifts. In oncology, the SY-2101 generic of Novartis's Jakavi has cleared Phase 1 approval, and industry expectations point to a possible launch after June 2028.

In anticancer contract manufacturing, large CDMO players such as Samsung Biologics are ahead on scale, so Samyang Biopharm differentiates through its dedicated cytotoxic facility and dual Japanese and European GMP certification.

On the platform side, an SK Securities note from an April 2026 company event described SENS as a hybrid nanoparticle platform that delivers nucleic acid therapies such as mRNA to specific tissues.

The same note noted that when platforms are licensed out, large pharma companies typically assign production to contract manufacturers such as Lonza or WuXi.

A 2025 press report said results from global technology transfers or export contracts were not yet clear, so the timing of cash conversion from the platform remains uncertain.

06

Outlook

In its 2025 securities filing, the company planned about KRW 49.3 billion in facility investment through 2026, including suture manufacturing equipment and mRNA production facilities.

The cytotoxic injectable plant has been completed with annual capacity of 5 million vials and holds Japanese and European GMP certifications.

In the pipeline, an SK Securities note from an April 2026 company event said the company has secured 11 SENS lead formulations, and the company has said it plans to pursue technology transfer based on its general-purpose delivery platform.

At its first regular shareholders meeting on March 23, 2026, CEO Kim Kyung-jin presented diversifying the medical device portfolio, entering aesthetic medicine, advancing SENS and expanding oncology sales as priorities.

The SY-2101 generic is in development after Phase 1 approval, and industry expectations place its launch after June 2028. The company's public direction is framed at the level of business priorities rather than numerical annual targets.

Actual 2026 facility spending and the operating rate of the injectable plant can be checked in the equipment investment section of the 2026 annual report. Whether technology transfer agreements are signed should be checked separately in disclosures and company IR materials. Overseas suture sales and fourth-quarter 2026 earnings will shape the medium-term direction.

07

Valuation

PER
—
PBR
1.3×
ROE
1.0%
EPS
—
BPS
₩32,091
Dividend per share
₩0

The price-to-book ratio sits in a range that is a premium to net asset value per share. Net assets are anchored to total equity of KRW 234.7 billion at the end of 2025, so growth in net assets depends on accumulated earnings.

The 2025 figures cover only two months, which makes direct comparison with full-year multiples difficult. The swing to an attributable net loss in the third quarter of 2026 also complicates interpretation of earnings-based multiples.

Dividend income is effectively absent at present, and cash has gone toward facilities and research. The share price reflects market expectations for sutures, oncology and platforms together, so the link between operating indicators and the price should be read separately.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Global suture leadership and an overseas-heavy revenue base

Biodegradable sutures hold the global number one share by thread supply volume and reach about 50 countries. Over November and December 2025, the export share was about 59%, with exports of KRW 16.8 billion against domestic sales of KRW 11.8 billion.

Another press report put overseas revenue above 80%, so the measurement basis differs. A structure that draws directly on overseas demand is cited as a strength.

Oncology manufacturing capacity and dual GMP certification

The dedicated cytotoxic injectable plant was expanded to annual capacity of 5 million vials, and the company says it is the only facility in Korea certified under both Japanese and European GMP. The oncology portfolio covers seven solid tumor types and five blood cancers.

The facility and certifications are assets that can serve contract manufacturing demand. Actual revenue contribution should be checked in the product breakdown of the annual report.

SENS platform and generic pipeline

The in-house SENS delivery system is presented as a way to carry nucleic acid therapies such as mRNA to target tissues. An April 2026 SK Securities note on a company event listed 11 SENS lead formulations.

The SY-2101 generic of Jakavi has cleared Phase 1, and industry expectations point to a possible launch after June 2028.

09

Bear factors

Weakening quarterly earnings

Second-quarter 2026 operating profit fell 46.2% quarter on quarter to KRW 746 million. Revenue slipped from KRW 35.9 billion in the second quarter to KRW 33 billion in the third. Third-quarter operating profit recovered to KRW 879 million, but an attributable net loss of KRW 174 million turned net income unstable. Quarter-to-quarter swings in profitability are cited as a weakness.

Revenue concentration and thin licensing track record

Company statements put the suture product group at 45% of total revenue. A 2025 press report said the oncology business is largely improved versions of existing drugs and that global licensing or export contract results are not yet clear.

Product-level results beyond sutures have not been disclosed in detail, which led to assessments that the earnings base is narrow.

Capex burden and a short reporting history

The 2025 securities filing planned about KRW 49.3 billion in facility investment through 2026. The disclosed record covers only the two months of 2025 and the first three quarters of 2026.

With operating cash flow of KRW 9.77 billion over those two months, whether internal cash continues to fund the investment program needs to be confirmed.

10

Risk factors

Business concentration

Earnings depend on two pillars, sutures and oncology. A high overseas revenue share means currency moves and regulatory changes in export markets can affect sales. Because product-level results are not disclosed in detail, variation across businesses is hard to gauge from outside.

Pipeline uncertainty

SENS-based drugs and technology transfers are at clinical or negotiation stages, so timing and outcomes are not set. The generic launch date is an industry expectation and could shift with approval and market conditions. Whether platform licensing translates into cash should be confirmed through contract disclosures.

Earnings volatility and a short history

The 2025 figures cover only two months, which makes annual trends hard to read. Operating profit and net income moved in different directions through 2026, and the third quarter showed a swing into loss.

The other segment's losses can offset profits from medical devices and pharmaceuticals, so the segment-level profit structure needs to be reviewed too.

11

What to watch next

  1. Late March 2027 (annual report filing deadline)

    The 2026 annual report will show fourth-quarter and full-year results, segment revenue and actual capex. It is the first point where the 9.4% operating margin from the two-month 2025 period can be compared with a full-year trend.

  2. End of December 2026 (fiscal year-end)

    Check whether the 2026 portion of the roughly KRW 49.3 billion investment plan has been completed and the operating rate of the injectable plant. These two items set the baseline for 2027 plant utilization and cost structure.

  3. After June 2028 (industry expected timing)

    Confirm whether and when the SY-2101 generic of Jakavi launches. If it does, the revenue mix centered on improved oncology drugs could change.

12

Overall view

Samyang Biopharm was spun off in November 2025 and has organized its business around global suture leadership, a dedicated injectable oncology plant and the SENS platform.

The disclosed 2025 figures cover only two months and show revenue of KRW 28.6 billion, an operating margin of 9.4% and attributable net income of KRW 2.24 billion, with a debt-to-equity ratio of 44.5%.

Quarterly revenue in 2026 moved through KRW 31.2 billion, KRW 35.9 billion and KRW 33 billion, while attributable net income went from KRW 2.57 billion to KRW 1.33 billion and then to a KRW 174 million net loss in the third quarter.

Strengths cited include overseas sales, suture market share, oncology facilities and certifications, and the generic pipeline. Weaknesses cited include product concentration in sutures, a thin licensing record and quarterly profit instability.

On valuation, the share price sits at a premium to net asset value per share, and dividend income is effectively absent. The next checkpoints are the 2026 annual report's full-year results and capex execution, and the generic launch timing expected after June 2028. Whether quarterly profits stabilize and whether SENS licensing turns into cash remain the core open questions.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. medicopharma.co.kr
  2. medigatenews.com
  3. biospectator.com
  4. newsthevoice.com
  5. startuptoday.co.kr
  6. newstomato.com
  7. dailypharm.com
  8. pharm.edaily.co.kr
  9. smedaily.co.kr
  10. pharm.edaily.co.kr
  11. kpinfo.kr
  12. butler.works
  13. sks.co.kr
  14. press9.kr
  15. m.news.nate.com
  16. eugenefn.com
  17. bloter.net

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis